PROJECT-003: MOLECULAR BIOLOGY AND CANCER GENETICS PROGRAM (MBCG) PROJECT SUMMARY / ABSTRACT The Molecular Biology & Cancer Genetics (MBCG) Program at The Ohio State University Comprehensive Cancer Center (OSUCCC), led by Michael Ostrowski, PhD and Matthew Ringel, MD, unites a highly productive, collaborative and cancer focused team of 44 basic and translational scientists representing 7 colleges and 18 academic departments at The Ohio State University. Program science is centered in four major cancer-focused scientific themes: small non-coding RNAs and cancer, human cancer genetics/genomics, signal transduction and therapeutic resistance, and tumor microenvironment. Program members utilize state-of-the-art approaches to 1) identify genes and pathways that fuel tumor cell initiation and growth, and 2) provide mechanistic details of how these genes and pathways contribute to tumor progression and therapeutic resistance. Our overall goal is to define the mechanisms that account for the association between genes and cancer and to exploit this knowledge in order to reduce the incidence of death from cancer.
The Specific Aims of the MBCG Program are: 1) to identify human genes, including non-coding genes such as those encoding microRNAs, that either through direct mutations or epigenetic mechanisms, result in an increased predisposition to cancer; 2) to determine the molecular mechanisms underlying the expression and function of the genes contributing to normal development, cancer progression, and therapeutic resistance; 3) to utilize the knowledge gained from gene identification and gene functions in tumorigenesis in order to reduce the incidence of death from cancer. During the prior funding period of the OSUCCC P30 CCSG, MBCG Program members published 810 research papers, including 104 high impact (> 10) manuscripts in journals such as Cell, Cancer Cell, Science, Nature Medicine, Nature Cell Biology, Journal of Clinical Oncology, and Journal of Clinical Investigation. There is extensive collaboration, with 21% intra-programmatic, 31% inter-programmatic, and 66% multi- institutional publications. Overall, 81% of MBCG publications are collaborative. MBCG Program members are principal investigators (PIs) on seven NCI programmatic grants, including a P01 and U01 in breast cancer (P01 CA097189, U01 CA154200), a P01 and P50 SPORE in thyroid cancer (P01 CA124570, P50 CA168505), a P01 in epigenetics (CA129242) and two U01s in lung cancer (U01 CA152758, U01 CA166905). They are PIs on CCSG-approved grants whose direct funding is currently $9.39 million, with $7.5 million in NCI funding (80% of total CCSG-approved funding). Program members are principal investigators on 21 active protocols that have accrued 5760 patients over the past five years. MBCG studies are predominantly interventional but non-therapeutic, and non-interventional as most of our interventional therapeutic work is accomplished collaboratively within the Translational Therapeutics and Leukemia Research Programs.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Rolfo, Christian; Mack, Philip C; Scagliotti, Giorgio V et al. (2018) Liquid Biopsy for Advanced Non-Small Cell LungĀ Cancer (NSCLC): A Statement Paper from theĀ IASLC. J Thorac Oncol 13:1248-1268
Ren, Yulin; Gallucci, Judith C; Li, Xinxin et al. (2018) Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens. J Nat Prod 81:554-561
McDonald, J Tyson; Kritharis, Athena; Beheshti, Afshin et al. (2018) Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. Oncotarget 9:22693-22702
Nguyen, Phuong; Wuthrick, Evan; Chablani, Priyanka et al. (2018) Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. Am J Clin Oncol 41:140-146
Elchuri, Sailaja V; Rajasekaran, Swetha; Miles, Wayne O (2018) RNA-Sequencing of Primary Retinoblastoma Tumors Provides New Insights and Challenges Into Tumor Development. Front Genet 9:170
Reiff, Sean D; Muhowski, Elizabeth M; Guinn, Daphne et al. (2018) Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Blood 132:1039-1049
Nabar, Gauri M; Mahajan, Kalpesh D; Calhoun, Mark A et al. (2018) Micelle-templated, poly(lactic-co-glycolic acid) nanoparticles for hydrophobic drug delivery. Int J Nanomedicine 13:351-366
Tang, Xiaowen; Yang, Lin; Li, Zheng et al. (2018) First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res 8:1083-1089
Lai, Xiulan; Stiff, Andrew; Duggan, Megan et al. (2018) Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proc Natl Acad Sci U S A 115:5534-5539
Reeves, Katherine W; Pennell, Michael; Foraker, Randi E et al. (2018) Predictors of vasomotor symptoms among breast cancer survivors. J Cancer Surviv 12:379-387

Showing the most recent 10 out of 2602 publications